Medicine and Dentistry
Breast Cancer
100%
Malignant Neoplasm
85%
Acute Myeloid Leukemia
85%
Human Immunodeficiency Virus
75%
Neoplasm
53%
Nodular Melanoma
51%
Leukemia Relapse
50%
Next Generation Sequencing
50%
Restylane
42%
Vincristine
42%
Sarcoma
42%
Metastatic Carcinoma
42%
Cyclophosphamide
42%
Hepatocellular Carcinoma
42%
Dyspareunia
42%
Etoposide
42%
Minimal Residual Disease
42%
Ifosfamide
42%
Mammography
42%
Randomized Controlled Trial
42%
Human Immunodeficiency Virus Infection
42%
Biological Marker
42%
Knee
42%
Osteoarthritis
42%
Movement Analysis
42%
Diabetes Mellitus
42%
Doxorubicin
42%
Non Melanoma Skin Cancer
42%
Lidocaine
42%
Mammogram
42%
Hepatic Portal Vein
42%
Systematic Review
42%
Insulin Resistance
42%
Stem Cell Therapy
42%
Sentinel Node
42%
Ulipristal
42%
Emergency Contraception
42%
Treatment Response
42%
Cancer Therapy
42%
Dynamic Contrast-Enhanced MRI
42%
Neoadjuvant Chemotherapy
42%
Disease
37%
Odds Ratio
34%
Anodyne
33%
Transplantation
30%
Glomerular Filtration Rate
28%
Cell Count
28%
Viral Load Testing
28%
Body Mass Index
26%
Drug Dose Reduction
25%
Keyphrases
Physical Function
85%
Insulin Resistance
85%
Type 1 Diabetes Mellitus (T1DM)
79%
HIV Patients
42%
HIV-negative
42%
Ewing-like
42%
Sentinel Node Metastasis
42%
HIV-positive
42%
Minimally Invasive Monitoring
42%
Risk Factors
42%
Quantile Residual Life
42%
Incident Diabetes Mellitus
42%
Acute Myeloid Leukemia Relapse
42%
Emergency Contraception
42%
Randomized Crossover Trial
42%
Ulipristal Acetate
42%
Double Dose
42%
Obesity
42%
Cobimetinib
42%
Pancreatic Cancer
42%
CASPER
42%
L-asparaginase
42%
Phase I Trial
42%
Gait Movement
32%
Asparagine Synthetase
32%
Asparagine
32%
Severe Knee Osteoarthritis
21%
Residual Life Distribution
21%
Metastatic Pancreatic Ductal Adenocarcinoma
21%
Pancreatic Ductal Adenocarcinoma
21%
MEK Inhibitor (MEKi)
21%
Tumor Killing
21%
Children with HIV
14%
Multicenter AIDS Cohort Study
12%
Multivariate Analysis
12%
Black Race
12%
Old Age
12%
Body Mass Index
12%
Short Form 36 (SF-36)
12%
Neuromuscular Changes
10%
Asymptotic Distribution
10%
Finite Sample Properties
10%
Clinical Benefit
10%
Glutamine
10%
Advanced or Metastatic
10%
Tolerability
10%
Starvation
10%
Tumor Cell Resistance
10%
Treatment Strategy
10%
RAS-MAPK Signaling
10%
